VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$6.34Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $477,527,552.00
EPSttm : -4.28
Verastem, Inc.
$6.34
0.96%$0.06Float Short %
25.34
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
0.81
EPS Last/This Y
0.94
EPS This/Next Y
1.06
Price
6.34
Target Price
16.62
Analyst Recom
1
Performance Q
-23.15
Relative Volume
0.41
Beta
0.39
Ticker: VSTM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-13 | VSTM | 7.2 | 0.21 | 0.25 | 11465 |
| 2026-01-14 | VSTM | 6.8 | 0.21 | 0.18 | 11513 |
| 2026-01-15 | VSTM | 6.59 | 0.20 | 0.44 | 11490 |
| 2026-01-16 | VSTM | 6.67 | 0.19 | 0.13 | 11331 |
| 2026-01-20 | VSTM | 6.64 | 0.07 | 0.00 | 5965 |
| 2026-01-21 | VSTM | 6.34 | 0.04 | 0.33 | 8250 |
| 2026-01-22 | VSTM | 6.68 | 0.05 | 0.37 | 8293 |
| 2026-01-23 | VSTM | 6.38 | 0.06 | 0.48 | 8618 |
| 2026-01-26 | VSTM | 6.23 | 0.06 | 0.05 | 8661 |
| 2026-01-27 | VSTM | 6.51 | 0.06 | 0.02 | 8715 |
| 2026-01-28 | VSTM | 6.24 | 0.06 | 0.30 | 8863 |
| 2026-01-29 | VSTM | 6.4 | 0.06 | 0.00 | 8971 |
| 2026-01-30 | VSTM | 6.09 | 0.06 | 0.38 | 9078 |
| 2026-02-02 | VSTM | 6.24 | 0.07 | 0.25 | 9090 |
| 2026-02-03 | VSTM | 6.3 | 0.07 | 0.40 | 9115 |
| 2026-02-04 | VSTM | 6.8 | 0.07 | 0.44 | 9124 |
| 2026-02-05 | VSTM | 6.3 | 0.07 | 4.21 | 9117 |
| 2026-02-06 | VSTM | 6.67 | 0.08 | 0.00 | 9218 |
| 2026-02-09 | VSTM | 6.65 | 0.08 | 0.00 | 9470 |
| 2026-02-10 | VSTM | 6.3 | 0.08 | 0.00 | 9468 |
| 2026-02-11 | VSTM | 6.34 | 0.08 | 1.59 | 9474 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-13 | VSTM | 7.20 | 20.0 | - | -2.73 |
| 2026-01-14 | VSTM | 6.80 | 20.0 | - | -2.73 |
| 2026-01-15 | VSTM | 6.59 | 20.0 | - | -2.73 |
| 2026-01-16 | VSTM | 6.67 | 20.0 | - | -2.73 |
| 2026-01-20 | VSTM | 6.64 | 20.0 | - | -2.73 |
| 2026-01-21 | VSTM | 6.34 | 20.0 | - | -2.73 |
| 2026-01-22 | VSTM | 6.67 | 20.0 | - | -2.73 |
| 2026-01-23 | VSTM | 6.38 | 20.0 | - | -2.73 |
| 2026-01-26 | VSTM | 6.23 | 20.0 | - | -2.73 |
| 2026-01-27 | VSTM | 6.51 | 20.0 | - | -2.73 |
| 2026-01-28 | VSTM | 6.24 | 20.0 | - | -2.73 |
| 2026-01-29 | VSTM | 6.41 | 20.0 | - | -2.73 |
| 2026-01-30 | VSTM | 6.09 | 20.0 | - | -2.73 |
| 2026-02-02 | VSTM | 6.24 | 20.0 | - | -2.73 |
| 2026-02-03 | VSTM | 6.30 | 20.0 | - | -2.73 |
| 2026-02-04 | VSTM | 6.80 | 20.0 | - | -2.73 |
| 2026-02-05 | VSTM | 6.30 | 20.0 | - | -2.73 |
| 2026-02-06 | VSTM | 6.66 | 20.0 | - | -2.73 |
| 2026-02-09 | VSTM | 6.66 | 20.0 | 125.8 | -2.73 |
| 2026-02-10 | VSTM | 6.30 | 20.0 | 132.4 | -2.73 |
| 2026-02-11 | VSTM | 6.34 | 20.0 | 124.2 | -2.73 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-13 | VSTM | -0.57 | 6.15 | 26.10 |
| 2026-01-14 | VSTM | -0.57 | 6.15 | 26.10 |
| 2026-01-15 | VSTM | -0.72 | 6.15 | 26.10 |
| 2026-01-16 | VSTM | -0.72 | 6.15 | 26.10 |
| 2026-01-20 | VSTM | -0.72 | 8.86 | 26.09 |
| 2026-01-21 | VSTM | -0.73 | 8.86 | 26.09 |
| 2026-01-22 | VSTM | -0.73 | 8.86 | 26.09 |
| 2026-01-23 | VSTM | -0.73 | 8.86 | 26.09 |
| 2026-01-26 | VSTM | -0.73 | 8.86 | 26.09 |
| 2026-01-27 | VSTM | -0.73 | 8.86 | 26.09 |
| 2026-01-28 | VSTM | -0.73 | 8.86 | 26.24 |
| 2026-01-29 | VSTM | -0.73 | 8.86 | 26.24 |
| 2026-01-30 | VSTM | -0.73 | 8.86 | 26.24 |
| 2026-02-02 | VSTM | -0.73 | 9.21 | 26.35 |
| 2026-02-03 | VSTM | -0.71 | 9.21 | 26.35 |
| 2026-02-04 | VSTM | -0.71 | 9.21 | 26.35 |
| 2026-02-05 | VSTM | -0.72 | 9.21 | 26.35 |
| 2026-02-06 | VSTM | -0.72 | 9.21 | 26.35 |
| 2026-02-09 | VSTM | -0.70 | 10.73 | 26.35 |
| 2026-02-10 | VSTM | -0.70 | 10.73 | 26.35 |
| 2026-02-11 | VSTM | -0.70 | 10.73 | 25.34 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.35
Avg. EPS Est. Current Quarter
-0.48
Avg. EPS Est. Next Quarter
-0.54
Insider Transactions
-0.7
Institutional Transactions
10.73
Beta
0.39
Average Sales Estimate Current Quarter
16
Average Sales Estimate Next Quarter
20
Fair Value
Quality Score
5
Growth Score
45
Sentiment Score
34
Actual DrawDown %
89.3
Max Drawdown 5-Year %
-96.2
Target Price
16.62
P/E
Forward P/E
PEG
P/S
35.69
P/B
P/Free Cash Flow
EPS
-4.26
Average EPS Est. Cur. Y
-2.73
EPS Next Y. (Est.)
-1.67
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1802.12
Relative Volume
0.41
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.29
EBIT Estimation
124.2
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading